DAVID W GRAINGER portrait
  • George S. and Dolores Doré Eccles Presidential Endowed Chair in Pharmaceutics/Pharmaceutical Chem., Pharmaceutical Chemistry
  • Chair, Bioengineering
  • Adjunct Professor, Chemistry
  • Distinguished Professor, Pharmaceutical Chemistry
  • Professor, Pharmaceutical Chemistry
  • Professor, Bioengineering
  • Distinguished Professor, Bioengineering
  • Adjunct Professor of Orthopedics, Orthopaedic Surgery Operations

Research Statement

My research interests and group focus on the crossroads of materials and medicine. I am interested in the thematic as well as literal interfaces of biomaterials and living systems. This translates to study and innovation in medical diagnostic systems and bioassays, medical implant designs and improvement using innovative biomaterials and on-baord drug delivery, implant-related infections, surface analysis in biomedical systems, drug delivery systems for proteins and vaccines, and novel surface modification strategies.

Research Keywords

  • Surface Chemistry
  • Polymer surface modification
  • Nanotechnology
  • Nanobiotechnology
  • Medical polymers
  • Medical Devices
  • Drug Delivery Systems
  • Diagnostics Assays
  • Biotechnology
  • Biomedical Engineering
  • Biomaterials
  • Ultrathin Protein and Polymer Films
  • Tissue Engineering
  • Protein-Surface Interaction
  • Protein Immobilization and Release
  • Polymeric drug delivery systems
  • Molecular Diagnostics
  • Membrane Biophysics
  • Gene Expression, Microarray
  • Fluorinated Surface Chemistry
  • Drug Delivery in Combination Services
  • Drug Delivery and Tissue Engineering
  • Drug Delivery
  • Diagnostic and Microarray Surfaces
  • Colloids
  • Cell-Surface Interaction
  • Brucella Vaccine
  • Biopharmaceutical and physicochemical problems related to dosage forms and drug delivery systems
  • Bioengineering
  • Bacteria-Surface Interaction

Presentations

  • “The Replaceable You: Medical Implant Function and Future”, Dunedin Rotary Club, New Zealand, March, 2016. Invited Talk/Keynote, Presented, 03/2106.
  • “Enduring the peer publication pressures with accurate nanomedicine research reporting”, Korean Academy of Science and Technology’s “Korean Young Scientists Research Conference on Revising Drug Delivery Research, Seoul, Korea, December 7, 2016. Invited Talk/Keynote, Presented, 12/07/2016.
  • “New directions for translating biofilm and device infection research”, 6th Thesinge Biofilms conference, Thesinge, The Netherlands, September 13, 2016. Invited Talk/Keynote, Presented, 09/13/2016.
  • "Translational Challenges to Antimicrobial Technologies, Biointerfaces International. Zürich, Switzerland, August 24, 2016. Invited Talk/Keynote, Presented, 08/24/2016.
  • “Credible and Curable: Biomedical Research Reliability for Nanomedicine“, Controlled Release Society annual meeting, Seattle, July 20, 2016. Invited Talk/Keynote, Presented, 07/20/2016.
  • "Combination medical devices to release drugs at implant sites”, New Zealand Chapter, Controlled Release Society, Auckland School of Pharmacy: University of Auckland, New Zealand, June 1, 2016. Invited Talk/Keynote, Presented, 06/01/2016.
  • “Barriers to medical device translation”, and session discussion leader, Translate! 2016, Berlin Germany, May 27, 2016. Invited Talk/Keynote, Presented, 05/27/2016.
  • “Nanomedicines: perceptions and realities in therapy and efficacy”, Controlled Release Society-AUS annual workshop, Monash Institute of Pharmaceutical Sciences, Melbourne, AUS, April. 2016. Invited Talk/Keynote, Submitted, 04/2016.
  • “Nanotechnology in medicine and its processing by the human body”, Abbey College Public lecture, Univ. Otago, Dunedin, New Zealand, April, 2016. Invited Talk/Keynote, Presented, 04/2016.
  • Invited talk: “Research challenges for clinical translation of antimicrobial device technologies,” U.S. Food and Drug Administration/CBE Workshop on Antimicrobial Devices, MD. Invited Talk/Keynote, Presented, 02/11/2015.
  • “Challenges in translating antimicrobial technologies to orthopedic implants”, Bombay Orthopedic Society’s Western India Regional Orthopedic Conference, Mumbai, India. Invited Talk/Keynote, Presented, 12/28/2014.
  • “High throughput drug screening methods: 2D vs 3D cell-based models“, MaterialsToday-Asia, Hong Kong, China. Invited Talk/Keynote, Presented, 12/12/2014.
  • “Value of multi-disciplinary research in modern science“, PacSurf 2014, Kona, HI, . Invited Talk/Keynote, Presented, 12/09/2014.
  • “Challenges in device and diagnostic development and translation“, D4 Drug delivery, diagnostic and medical device conference, Otago, New Zealand. Invited Talk/Keynote, Presented, 11/25/2014.
  • The 58th Annual Edward T. Smith Orthopaedic Lectureship, “Biologics for Orthopaedics – Where Are We in 2014 and the Future?, University of Texas-Houston, Department of Orthopaedic Surgery. Invited Talk/Keynote, Presented, 11/14/2014.
  • “Lost in Translation: Lessons learned from translating antimicrobial technologies”, A3 Foresight International Symposium on Nano-Biomaterials, Tokyo, Japan. Invited Talk/Keynote, Presented, 10/09/2014.
  • “Be it resolved that regulatory pathways hinder effective translation of antimicrobial technologies to address dire unmet clinical needs in addressing implant-centered infections”, (proponent), Biointerface 2014, Redwood City, CA. Invited Talk/Keynote, Presented, 10/07/2014.
  • “Lost in Translation: Lessons learned from translating antimicrobial technologies”, 33rd annual meeting, European Bone and Joint Infection Society, Utrecht, NL. Invited Talk/Keynote, Presented, 09/11/2014.
  • “Getting to the nitty-gritty: oral ingestion of nanoparticles, intestinal processing, bioavailability and potential toxicity assessment challenges", ILSI North America Workshop on “The Role and Use of Nutritional Studies in Evaluating the Safety of a Food or Ingredient,” Washington, DC. Invited Talk/Keynote, Presented, 07/22/2014.
  • “Prospects for 3D cell culture assays to improve future drug development“, 41st Annual Meeting & Exposition of the
Controlled Release Society, Chicago, IL. Invited Talk/Keynote, Presented, 07/14/2014.
  • “Multi-technique analysis of immobilized protein and DNA patterns”, Am. Chem. Soc. NORM meeting, Missoula, MT. Invited Talk/Keynote, Presented, 06/24/2014.
  • Identifying the Challenges in Translation”, and Panel Moderator, Translate! 2014, Berlin, Germany. Invited Talk/Keynote, Presented, 05/22/2014.
  • “Device-based therapeutic drug delivery,” IADDS 2104, Taipei, Taiwan. Invited Talk/Keynote, Presented, 04/30/2014.
  • “Comparing 2-D versus 3-D cell screening systems in drug development”, Joint AAPS-China CPS Workshop on Emerging Trends in Cell-based Therapeutics,” Shanghai, China. Invited Talk/Keynote, Presented, 04/25/2014.
  • “Comparing nanoparticle and classic microparticle in vivo fates“, Federation Internationale Pharmaceutics, Melbourne, Australia. Invited Talk/Keynote, Presented, 04/13/2014.
  • “Lost in Translation: Antimicrobial Implant Technologies,” University of Otago, Centre for Bioengineering, Dunedin, New Zealand. Invited Talk/Keynote, Presented, 04/11/2014.
  • “Nano vs Microparticle Biodistributions: Has Anything Changed?,” Otago Postgraduate Medical Society Visiting Lecturer, School of Medicine, University of Otago, Dunedin, New Zealand. Invited Talk/Keynote, Presented, 04/10/2014.
  • “Physico-chemical concepts for nanoparticle interactions with oral barriers”, BioBarriers2014, Saarbrücken, Germany. Invited Talk/Keynote, Presented, 02/16/2014.
  • “Current translational challenges in nanomaterials characterization,” 60th AVS International Surface Science Symposium, Long Beach, CA. Invited Talk/Keynote, Presented, 10/31/2013.
  • Oral processing of nanotechnology”, East China Normal University. Invited Talk/Keynote, Presented, 10/29/2013.
  • “Comparing bioavailabilities of oral and injected nanomaterials”, Fudan University, Shanghai, China,. Invited Talk/Keynote, Presented, 10/28/2013.
  • “Device-based delivery of protein and siRNA therapeutics”, 2013 China Controlled Release Society and 2013 Chinese Pharmaceutical Conference. Invited Talk/Keynote, Presented, 10/26/2013.
  • “Device-based delivery of protein and siRNA therapeutics”, 2013 China Controlled Release Society and 2013 Chinese Pharmaceutical Conference. Invited Talk/Keynote, Presented, 10/26/2013.
  • “Potent blood clotting mechanisms for cationic dendrimers,” Polymers in Advanced Technologies. Invited Talk/Keynote, Presented, 09/30/2013.
  • , “Comparing in vitro and in vivo behaviors of nanotechnology”, Swiss Competence Centre for Materials Science and Technology, EU Project NanoDiaRA annual workshop. Invited Talk/Keynote, Presented, 09/27/2013.
  • Lost in translation: comparing in vitro and in vivo antimicrobial device outcomes”, Engineering Life Symposium. Invited Talk/Keynote, Presented, 09/18/2013.
  • “Prospects for 3D cell culture assays to improve future drug development“, Department of Bioengineering, University California-Berkeley, CA. Invited Talk/Keynote, Presented, 09/03/2013.
  • “Potent blood clotting mechanisms for cationic dendrimers”, Tsukuba International Conference on Materials Science, Tsukuba, Japan. Invited Talk/Keynote, Presented, 08/29/2013.
  • “Comparing biodistributions of micro- and nano-particles”, Society of Toxicology-3M joint workshop, St. Paul, MN,. Invited Talk/Keynote, Presented, 08/01/2013.
  • “A tale of two species: 1. nanomaterials fate in vivo and 2. medical device-associated infection,” National Institute of Standards and Technology, Shady Grove,, MD. Invited Talk/Keynote, Presented, 07/26/2013.
  • “Cationic dendrimer nanoparticles as powerful procoagulant stimulus,” Joint Symposia of the 5th U&I DDS Research Center and 7th International Intelligent Drug Delivery. Invited Talk/Keynote, Presented, 05/22/2013.
  • “Nanomaterial use and abuse: technical challenges in moving nanotechnologies to in vivo applications, 5th WMRIF (World Materials Research Institute Forum) General Assembly and Symposium “Materials meets Life”, Dübendorf, Switzerland. Invited Talk/Keynote, Presented, 05/14/2013.
  • “The Utah Artificial Heart Program: A piece of history”, Department of Bioengineering, University of Utah, Salt Lake City, UT. Invited Talk/Keynote, Presented, 03/01/2013.
  • “Local delivery of biopharmaceuticals from medical devices”, 40th USA-Korea Conference on Science and Technology, Park City, UT, August 13, 2011. Invited Talk/Keynote, Presented, 08/13/2011.
  • “Chemistry, Drugs and Materials in Biomedical Device Design,” Willamette University, Salem, OR, November 17, 2010. Invited Talk/Keynote, Presented, 11/17/2010.

Research Equipment and Testing Expertise

  • Access to University Core Lab facilities as described on-line for the University, including the imaging, microscopy, histology, flow cytometry, and bioanalytical chemistry, and the Nano-Fab core facility with surface analysis tools, including imaging XPS and ellipsometry, SEM and TEM. Contact: David Grainger , , Bioengineering.

Languages

  • English, fluent.
  • German, functional.

Geographical Regions of Interest

  • Australia and New Zealand
    2016 Fulbright Senior Scholar.
  • Germany
    Humboldt Foundation postdoctoral fellow, Mainz, 1989 Helmholtz Foundation programme reviewer, 2014 Brandenburg Center for Regenerative Medicine, Berlin, 2013-2016.
  • Japan
    frequent invited guest and JSPS Visiting Faculty Fellow, Tokyo Women's Medical University, 1998.
  • Netherlands
    regular visitor and consultant to the Institute of Biomedical Engineering, Royal University of Groningen.
  • Republic of Korea
    Joint Inha-Utah Drug Delivery Center, Inha, Korea.
  • Sweden
    Scientific Advisor to FORMAMP (EU FP7 R&D Centre on antimicrobial peptides) Umea, Sweden.
  • Switzerland
    advisor to the AO Foundation, EMPA, TEDD, and the CCMX Board Chair, Materials Science Initiative, Switzerland.
  • United Kingdom of Great Britain and Northern Ireland
    Scientific Advisor to EPSRC Next Generation Biomaterials Discovery Programme R&D Centre, University of Nottingham, U.K.

Publications

  • Christie, R. James, Pollard, Emily J., Olsen, Steven C., Grainger, David W. & Falconer, Jonathan L. (2016). Live RB51 vaccine lyophilized hydrogel formulations with increased shelf life for practical ballistic delivery. Elsevier BV. Vol. 498(1-2), 187-194. Published, 2016.
  • Jones Z., Brooks A., Ferrell Z., Grainger D.W. & Sinclair K. (2016). A resorbable antibiotic eluting bone void filler for periprosthetic joint infection prevention. (pp. 1632-1642). Vol. 104. Journal of Biomedical Materials Research - Part B Applied Biomaterials. Published, 11/01/2016.
  • Deans T., Grainger D.W. & Fussenegger M. (2016). Synthetic Biology: Innovative approaches for pharmaceutics and drug delivery. (pp. 1-2). Vol. 105, Advanced Drug Delivery Reviews. Published, 10/01/2016.
  • K.Z. Meidell, R. Robinson, A.V. de Abreu, A.J. Gormley, H. Ghandehari, D.W. Grainger, R. Campbell, “RGDfK-functionalized gold nanorods bind only to activated platelets,” J. Biomed. Mater. Res., A. 2017 Jan;105(1):209-217. doi: 10.1002/jbm.a.35902; PMID: 27648522. Published, 10/2016.
    https://www.ncbi.nlm.nih.gov/pubmed/27648522
  • Deans TL, Grainger DW & Fussenegger M (2016). Synthetic Biology: Innovative approaches for pharmaceutics and drug delivery. Advanced drug delivery reviews. Vol. 105, 1-2. Published, 09/01/2016.
  • Deans TL, Grainger DW & Fussenegger M (2016). Synthetic Biology: Innovative approaches for pharmaceutics and drug delivery. Advanced drug delivery reviews. Vol. 105, 1-2. Published, 09/01/2016.
  • Abou-El-Enein M, Duda GN, Gruskin EA & Grainger DW (2016). Strategies for Derisking Translational Processes for Biomedical Technologies. Trends in biotechnology. Vol. 35, 100-108. Published, 08/01/2016.
  • Abou-El-Enein M, Duda GN, Gruskin EA & Grainger DW (2016). Strategies for Derisking Translational Processes for Biomedical Technologies. Trends in biotechnology. Vol. 35, 100-108. Published, 08/01/2016.
  • M. Abou-El-Enein, G.N. Duda, E. Gruskin, D.W. Grainger,Strategies for De-Risking Translational Processes in Biomedical Science and Technology,” Trends Biotechnol.,, ePub, 2016 (DOI: http://dx.doi.org/10.1016/j.tibtech.2016.07.007). Published, 08/2016.
    http://dx.doi.org/10.1016/j.tibtech.2016.07.007
  • Winters AA, Bou-Ghannam S, Thorp H, Hawayek JA, Atkinson DL, Bartlett CE, Silva FJ, Hsu EW, Moreno AP, Grainger, DW, Patel AN, Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease, Cell Transplant. 2016 May 10. [Epub ahead of print]. PMID: 27165370. Published, 05/2016.
  • Aamodt JM & Grainger DW (2016). Extracellular matrix-based biomaterial scaffolds and the host response. Biomaterials. Vol. 86, 68-82. Published, 03/01/2016.
  • J. Aamodt, D.W. Grainger, Extracellular Matrix-based Biomaterial Scaffolds and the Host Response, Biomaterials, (2016) 86 68–82. doi:10.1016/j.biomaterials.2016.02.003. Published, 03/2016.
    http://dx.doi.10.1016/j.biomaterials.2016.02.003
  • C.F. Jones, D.G. Castner, D.W. Grainger, “Surface Adsorbate Processing on Nanomaterials in Host Immune and Toxicological Processing”, Chapter 6 in Handbook of Immunological Properties of Engineered Nanomaterials (Volume 1: Key Considerations for Nanoparticle Characterization Prior to Immunotoxicity Studies), 2nd ed., (M. Dubrovolaskia, S. McNeil, eds.), World Scientific Press, Singapore, ISBN: 978-981-4699-16-7. 2016, pp. 376. Published, 02/01/2016.
  • Falconer JL, Christie RJ, Pollard EJ, Olsen SC & Grainger DW (2016). Live RB51 vaccine lyophilized hydrogel formulations with increased shelf life for practical ballistic delivery. International journal of pharmaceutics. Vol. 498, 187-94. Published, 01/01/2016.
  • M. Avula, D. Jones; A. Rao, D. McClain, L.D. McGill, D.W. Grainger; F. Solzbacher, “Local release of masitinib alters in vivo implantable continuous glucose sensor performance”, Biosensors Bioelectron. (2016) 77 149–156;DOI 10.1016/j.bios.2015.08.059. Published, 01/2016.
  • J.L. Falconer, R.J. Christie, E.J. Pollard, S.C. Olsen, D.W. Grainger, “Live RB51 Vaccine Lyophilized Hydrogel Formulations with Increased Shelf Life for Practical Ballistic Delivery,” Int. J. Pharm, 498 (2016) 187–194. PMID: 26705151. Published, 01/2016.
  • Gustafson HH, Holt-Casper D, Grainger DW & Ghandehari H (2015). Nanoparticle Uptake: The Phagocyte Problem. Nano today. Vol. 10, 487-510. Published, 12/01/2015.
  • Avula M, Jones D, Rao AN, McClain D, McGill LD, Grainger DW & Solzbacher F (2015). Local release of masitinib alters in vivo implantable continuous glucose sensor performance. Biosensors & bioelectronics. Vol. 77, 149-56. Published, 12/01/2015.
  • Grainger DW & Bae YH (2015). The 17th International Symposium on Recent Advances in Drug Delivery, June 14-17, 2015, Salt Lake City, UT, USA. Preface. (pp. 569-70). Vol. 220. Journal of controlled release : official journal of the Controlled Release Society. Published, 12/01/2015.
  • Avula M, Jones D, Rao AN, McClain D, McGill LD, Grainger DW & Solzbacher F (2015). Local release of masitinib alters in vivo implantable continuous glucose sensor performance. (pp. 149-56). Vol. 77. Biosensors & bioelectronics. Published, 12/01/2015.
  • M.N. Avula, D.W. Grainger, “Addressing medical device challenges with drug/device combinations,” Chapter 3, in Drug-Device Combinations for Chronic Diseases, R. Siegel., S.P. Lyu, eds., Wiley, New York, ISBN: 978-1-118-12000-2, 280 pp., 2015. Published, 10/01/2015.
  • Hofmann-Amtenbrink M, Grainger DW & Hofmann H (2015). Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations. Nanomedicine : nanotechnology, biology, and medicine. Vol. 11, 1689-94. Published, 09/01/2015.
  • Auer JA & Grainger DW (2015). Fracture management in horses: Where have we been and where are we going?. Veterinary journal (London, England : 1997). Vol. 206, 5-14. Published, 09/01/2015.
  • Jones Z, Brooks AE, Ferrell Z, Grainger DW & Sinclair KD (2015). A resorbable antibiotic eluting bone void filler for periprosthetic joint infection prevention. Journal of biomedical materials research. Part B, Applied biomaterials. Vol. 104, 1632-1642. Published, 09/01/2015.
  • H.-D. Volk, M.M. Stevens, D.J. Mooney, D.W. Grainger,, G.N. Duda, Key elements for nourishing the translational research environment. Sci. Transl. Med. 7, 282cm2 (2015). Published, 09/2015.
  • D.W. Grainger, “Wound healing: enzymatically crosslinked scaffolds,” Nature Materials 14, 662–663 (2015) doi:10.1038/nmat4337, 2015. (PMID 26099714). Published, 09/2015.
    http://dx.doi.10.1038/nmat4337
  • M. Hofmann-Amtenbrink, D.W. Grainger, H. Hofmann, “Nanoparticles in Medicine: Current Challenges Facing Inorganic Nanoparticle Toxicity Assessments and Standardizations,” Nanomedicine, 2015, 11(7) 1689–1694; DOI: http://dx.doi.org/10.1016/j.nano.2015.05.005. Published, 09/2015.
    http://dx.doi.org/10.1016/j.nano.2015.05.005
  • D.W. Grainger, “Fat prospects for healing cutaneous wounds: new activities under the sheets,” Diabetes (commentary), 64: 2717-2719, 2015. Published, 08/2015.
  • Grainger DW (2015). Fat Prospects for Healing Cutaneous Wounds: New Activities Under the Sheets. (pp. 2717-9). Vol. 64. Diabetes. Published, 07/01/2015.
  • Chamberlain LM, Holt-Casper D, Gonzalez-Juarrero M & Grainger DW (2015). Extended culture of macrophages from different sources and maturation results in a common M2 phenotype. Journal of biomedical materials research. Part A. Vol. 103, 2864-74. Published, 07/01/2015.
  • Chamberlain LM, Holt-Casper D, Gonzalez-Juarrero M & Grainger DW (2015). Extended culture of macrophages from different sources and maturation results in a common M2 phenotype. Journal of biomedical materials research. Part A. Vol. 103, 2864-74. Published, 07/01/2015.
  • Grainger DW (2015). Wound healing: Enzymatically crosslinked scaffolds. (pp. 662-3). Vol. 14. Nature materials. Published, 06/01/2015.
  • Holt-Casper D, Theisen JM, Moreno AP, Warren M, Silva F, Grainger DW, Bull DA & Patel AN (2015). Novel xeno-free human heart matrix-derived three-dimensional scaffolds. Journal of translational medicine. 13:194, 2015. (PMID 26084398). Published, 06/01/2015.
  • J. Auer, D.W. Grainger, “Fracture management in horses: Where have we been and where are we going?”, Vet. J., ePub June 20, 2015; doi: 10.1016/j.tvjl.2015.06.002. (PMID 26095036). Published, 06/2015.
    http://dx.doi.10.1016/j.tvjl.2015.06.002
  • J. Falconer, S. Lu, C. Jones, D.W Grainger,Carbon Nanomaterials Rescue Polyaromatic Hydrocarbon Toxicity in Zebrafish Embryo Cultures”, Environ. Sci. Nano, 2015, 2, 645 – 652; DOI: 10.1039/C5EN00111K. Published, 06/2015.
  • A. Rao, M.N. Avula, D.W. Grainger, “Aging and the host response to implanted biomaterials,” in Host Response to Biomaterials, S. Badylak, ed., Elsevier, Amsterdam, ISBN: 978-0-12-800196-7; 2015, pp. 269-303. Published, 06/01/2015.
  • Volk HD, Stevens MM, Mooney DJ, Grainger DW & Duda GN (2015). Key elements for nourishing the translational research environment. Science translational medicine. Vol. 7, 282cm2. Published, 04/01/2015.
  • Brooks BD, Sinclair KD, Grainger DW & Brooks AE (2015). A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model. PloS one. Vol. 10, e0118696. Pending, 03/01/2015.
  • Brooks BD, Sinclair KD, Grainger DW & Brooks AE (2015). A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model. PloS one, 2015 Mar 27;10(3):e0118696. doi: 10.1371/journal.pone.0118696D. PMID: 25815727. Published, 03/01/2015.
  • D.J. Holt, A. Moreno, M. Warren, J.M. Theisen, D.W. Grainger, D.A. Bull, A.N. Patel, Highly cellularized three-dimensional human heart matrix-derived scaffolds, J. Trans. Med., 13:194, 2015. (PMID 26084398). Published, 03/2015.
  • H. Herd Gustafson, D. Holt-Casper, D.W. Grainger, H. Ghandehari,, “Nanoparticle Uptake: The Phagocyte Problem“, NanoToday, 2015 Aug; 10(4): 487-510. doi: 10.1016/j.nantod.2015.06.006; PMCID: PMC4666556; NIHMSID: NIHMS707252. Published, 03/2015.
    http://dx/doi.10.1016/j.nantod.2015.06.006
  • Astashkina AI, Mann BK, Prestwich GD & Grainger DW (2014). 'Erratum to "Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines" [Biomaterials 33 (2012) 4712-4721]'. (pp. 108). Vol. 38. Biomaterials. Published, 12/01/2014.
  • Astashkina AI, Mann BK, Prestwich GD & Grainger DW (2014). 'Erratum to "Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines" [Biomaterials 33 (2012) 4712-4721]'. (pp. 108). Vol. 38. Biomaterials. Published, 12/01/2014.
  • Degooyer J, Davidoff SN, Brooks BD, Grainger DW & Brooks AE (2014). Polymer-controlled extended combination release of silver and chlorhexidine from a bone void filler. Biomedical sciences instrumentation. Vol. 50, 47-53. Published, 11/01/2014.
  • Duda GN, Grainger DW, Frisk ML, Bruckner-Tuderman L, Carr A, Dirnagl U, Einhäupl KM, Gottschalk S, Gruskin E, Huber C, June CH, Mooney DJ, Rietschel ET, Schütte G, Seeger W, Stevens MM, Urban R, Veldman A, Wess G & Volk HD (2014). Changing the mindset in life sciences toward translation: a consensus. Science translational medicine. Vol. 6, 264cm12. Published, 11/01/2014.
  • Moriarty TF, Grainger DW & Richards RG (2014). Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections. European cells & materials. Vol. 28, 112-28; discussion 128. Pending, 09/01/2014.
  • Brooks BD, Sinclair KD, Davidoff SN, Lawson S, Williams AG, Coats B, Grainger DW & Brooks AE (2014). Molded polymer-coated composite bone void filler improves tobramycin controlled release kinetics. Journal of biomedical materials research. Part B, Applied biomaterials. Vol. 102, 1074-83. Published, 06/01/2014.
  • Grainger DW (2014). Cell-based drug testing; this world is not flat. Advanced drug delivery reviews. Vol. 69-70, vii-xi. Published, 05/01/2014.
  • Astashkina AI, Jones CF, Thiagarajan G, Kurtzeborn K, Ghandehari H, Brooks BD & Grainger DW (2014). Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model. Biomaterials. Vol. 35, 6323-31. Published, 05/01/2014.
  • Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW & Ying W (2014). A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. (pp. 479-87). Vol. 11. International journal of medical sciences. Pending, 04/01/2014.
  • Avula MN, Rao AN, McGill LD, Grainger DW & Solzbacher F (2014). Foreign body response to subcutaneous biomaterial implants in a mast cell-deficient Kit(w-Sh) murine model. Acta biomaterialia. Vol. 10, 1856-63. Published, 04/01/2014.
  • “A Critical Comparison of Protein Microarray Fabrication Technologies”, Analyst, 2014 Feb 17;139(6):1303-26. doi: 10.1039/c3an01577g. Published, 02/17/2014.
  • “A 3-D organoid in vitro kidney model for in vivo nanomaterials toxicity assessment,” Biomaterials, 10.1016/j.biomaterials.2014.04.060, 2014.. Published, 02/05/2014.
  • “Foreign Body Response To Subcutaneous Biomaterial Implants in a Mast Cell-deficient Kitw-Sh Murine Model,” Acta Biomaterialia, 10(5):1856-63. doi: 10.1016/j.actbio.2013.12.056, 2014. PMID: 24406200. Published, 02/04/2014.
  • “Biophysical aspects of nucleic acids on surfaces relevant to microarray performance, Biomaterials. Sci., (2014) 2(4), 436-471. DOI:10.1039/C3BM60181A. Published, 02/04/2014.
    http://dx/DOI.10.1039/C3BM60181A
  • “Barriers to Advancing Nanotechnology to Better Improve and Translate Nanomedicines" Front. Chem. Sci. Eng., (2014) 8(3): 265-275; DOI: 10.1007/s11705-014-1442-x. Published, 02/04/2014.
  • Changing the Mindset in Life Sciences toward Translation: A Consensus, Sci, Trans. Med. 6, 264cm12 (2014). Published, 02/03/2014.
  • Romanov V, Davidoff SN, Miles AR, Grainger DW, Gale BK & Brooks BD (2014). A critical comparison of protein microarray fabrication technologies. (pp. 1303-26). Vol. 139. The Analyst. Published, 02/01/2014.
  • “Metabolically active human brown adipose tissue derived stem cells”, Stem Cells, 32: 572–581; doi: 10.1002/stem.1595. Published, 02/01/2014.
  • “A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs,” Intl J. Med Sci., 2014; 11(5): 479-487. doi: 10.7150/ijms.8340. Published, 02/01/2014.
  • Silva FJ, Holt DJ, Vargas V, Yockman J, Boudina S, Atkinson D, Grainger DW, Revelo MP, Sherman W, Bull DA & Patel AN (2014). Metabolically active human brown adipose tissue derived stem cells. Stem cells (Dayton, Ohio). Vol. 32, 572-81. Published, 01/01/2014.
  • Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections, Eur Cells Mater. 28 112-128 (2014). Published, 01/01/2014.
  • Comparisons of release of several antibiotics from antimicrobial polymer-coated allograft bone void filler,” Intl J. Biomed. Mat. Res., 2013; 1(2): 21-25; published online January 10, 2014 (http://www.sciencepublishinggroup.com/j/ijbmr); doi: 10.11648/j.ijbmr.20130102.11. Published, 01/01/2014.
    http://www.sciencepublishinggroup.com/j/ijbmr
  • Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments,” Adv. Drug Del. Rev. 69:1-8, 2014.. Published, 01/01/2014.
  • “Cell-based drug testing; this world is not flat”, Adv. Drug Del. Rev, 69:vii-xi (2014) 10.1016/j.addr.2014.04.001.. Published, 01/01/2014.
  • Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW & Deering-Rice CE (2013). In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine : nanotechnology, biology, and medicine. Vol. 10, 1-9. Published, 12/01/2013.
  • Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger DW & Munger MA (2013). Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation. (pp. 328-33). Vol. 8. Nanotoxicology. Published, 12/01/2013.
  • D.W. Grainger, H.C. van der Mei, P.C. Jutte, J.J.A.M. van den Dungen, M.J. Schultz, B.F.A.M. van der Laan, S.A.J. Zaat, H.J. Busscher, “Critical factors in the translation of improved antimicrobial strategies for medical implants and devices”, Biomaterials, 2013 Dec;34(37):9237-43. doi: 10.1016/j.biomaterials.2013.08.043. Epub 2013 Sep 11, PMID: 24034505. Published, 12/2013.
    http://dx/doi.10.1016/j.biomaterials.2013.08.043
  • “Multi-technique characterization of DNA-modified surfaces for biosensing and diagnostic applications” in “Surface Analysis and Techniques in Biology”, (Chapter 11) in “Surface Analysis and Techniques in Biology, ed. V. S. Smentkowski, Springer AG, London, (2013), pp. 289-314; DOI 10.1007/978-3-319-01360-2. Published, 09/10/2013.
  • “Critical factors in the translation of improved antimicrobial strategies for medical implants and devices”, Biomaterials, 2013 Dec;34(37):9237-43. doi: 10.1016/j.biomaterials.2013.08.043. Epub 2013 Sep 11, PMID: 24034505. Published, 09/01/2013.
  • “Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib, Biomaterials 34 9737-9746 (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.08.090. Published, 02/05/2013.
    http://dx.doi.org/10.1016/j.biomaterials.2013.08.0...
  • F. Liu, D.W. Grainger, “Fluorinated Biomaterials” in Biomaterials Science, 3rd ed., B.D. Ratner, A.S. Hoffman, J. Lemons, F. Schoen, eds., Academic Elsevier, Amsterdam, 2013, pp. 92-103 (Chapter 1.1.2c) ISBN-10: 0123746264, ISBN-13: 978-0123746269. Published, 02/01/2013.
  • Correction to the Supporting information of Real-time fluorescent image analysis of DNA spot hybridization kinetics to assess microarray spot heterogeneity,” Anal. Chem. 85(8) 4199 (2013). PMID 23551146. Published, 02/01/2013.
  • “In vivo human time-exposure study of orally dosed commercial silver nanoparticles,” Nanomedicine: NBM, 2013;xx:1-9, http://dx.doi.org/10.1016/j.nano.2013.06.010. Published, 02/01/2013.
  • “Polymer-controlled release of tobramycin from bone graft void filler,” Drug Deliv. Transl. Res., (2013) 3:518530; DOI 10.1007/s13346-013-0155-x. Published, 02/01/2013.
  • “Connecting drug delivery reality to smart materials design,” Int. J. Pharm, 454 (2013) 521-524; doi:10.1016/j.ijpharm.2013.04.061. Published, 02/01/2013.
  • “Molded Polymer-Coated Composite Bone Void Filler Improves Tobramycin Controlled Release Kinetics", J. Biomed. Mat. Res. B (Appl. Biomaterials), 2013 102(5):1074-83. doi: 10.1002/jbm.b.33089, PMID: 24376164. Published, 02/01/2013.
    http://dx/doi.10.1002/jbm.b.33089
  • D.W. Grainger, “All charged up about biomaterials,” (News and Views), Nature Biotechnol., 31, 507–509 (2013) doi:10.1038/nbt.2600. Published, 02/01/2013.
    http://dx/doi.10.1038/nbt.2600
  • K.J. Smock, R.L. Schmidt, G. Hadlock, G. Stoddard, D.W. Grainger, M.A. Munger, “Assessment of Orally Dosed Commercial Silver Nanoparticles on Human ex vivo Platelet Aggregation,” Nanotoxicol., 2014 8(3):328-33 (PMID: 23517080). DOI: 10.3109/17435390.2013.788749. Published, 01/2013.
    http://dx.doi.10.3109/17435390.2013.788749
  • A.E. Brooks, B.D. Brooks, S.N. Davidoff, P.C. Hogrebe, M.A. Fisher, and D.W. Grainger, “Polymer-controlled release of tobramycin from bone graft void filler,” Drug Deliv. Transl. Res., (2013) 3(6):518530; DOI 10.1007/s13346-013-0155-x. Published, 01/2013.
    http://dx/doi.10.1007/s13346-013-0155-x
  • “Developing siRNA therapies to address osteoporosis“, Therap. Deliv., 4(10):1239-46 (2013). doi: 10.4155/tde.13.85. Published, 01/01/2013.
  • B. Brooks, A. Brooks. D.W. Grainger, “Antimicrobial Technologies in Preclinical and Clinical Medical Devices”, Chapter 13 in ‪Biomaterials Associated Infection: Immunological Aspects and Antimicrobial Strategies, T. F. Moriarty, S.A.J. Zaat, H. Busscher, eds., Springer Verlag, New York, 2012, pp. 307-354; ISBN 978-1-4614-1030-0. Published, 02/02/2012.
  • “Surface analytical methods: in situ and UHV techniques” in Comprehensive Biomaterials – vol 3, chapter 301, eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam (ISBN 978-0-08-055302-3), 2011, pp 1-22. Published, 07/2011.
  • “Cultured Primary Macrophage Activation by Lipopolysaccharide Depends on Adsorbed Protein Composition and Substrate Surface Chemistry“, J. Biomater. Sci. Polym. Ed., e-pub, June, 2011, DOI:10.1163/092050611X580382; PMID: 21722418. Published, 06/2011.
  • “Nanotechnology Environmental, Health, and Safety Issues,” Chapter 4 in: Nanotechnology Research Directions for Societal Needs in 2020: Retrospective and Outlook (M.C. Roco, C.A. Mirkin, M.C. Hersam, eds.) NSF/WTEC report, 2011,
Springer, Boston, USA, pp. 610. Published, 06/2011.
  • “Fluorinated Biomaterials” in Comprehensive Biomaterials vol 1, Chapter 128, eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam (ISBN 978-0-08-055302-3), 2011, pp 513-525. Published, 05/2011.
  • “Chapter 5: Cell-Materials Interactions: Fundamental Design Issues for Tissue Engineering and Clinical Considerations”, in An Introduction to Biomaterials, 2nd ed. (J.O. Hollinger, ed.), CRC Press, Boca Raton, FL, ISBN-13: 978-1439812563, (2011). Published, 04/2011.
  • “Simultaneous interaction of staphylococci and osteoblasts in co-culture crosslinked poly(ethylene glycol)-based polymer coatings” Biomaterials, 32 (2011) 979-984; doi 10.1016/j.biomaterials.2010.10.011 PMID: 20980049. Published, 01/2011.
  • “Chapter 6: Host-Implant Response”, in An Introduction to Biomaterials, 2nd ed., (J.O. Hollinger, ed), CRC Press, Boca Raton, FL, ISBN-13: 978-1439812563, (2011). Published, 01/2011.
  • F. Liu, D.W. Grainger, Chapter 40: “Fluorinated Biomaterials” in Comprehensive Biomaterials – an on-line compendium, Elsevier, Amsterdam, 2010, in press. In press, 12/2010.
  • D.G. Castner, D.W. Grainger, Chapter 82: “Surface analytical methods: in situ and UHV techniques” in Comprehensive Biomaterials – an on-line compendium, Elsevier, Amsterdam, 2010, in press. In press, 12/2010.
  • G. Harbers, D.W. Grainger, “Chapter 3: Cell-Materials Interactions: Fundamental Design Issues for Tissue Engineering and Clinical Considerations”, in An Introduction to Biomaterials, 2nd ed. (J.O. Hollinger, S. Guelcher, eds), CRC Press, Boca Raton, FL, in press, 2009. In press, 11/2010.
  • “siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption,” Pharm. Res., 27(7) 1273-1279, (2010). doi 10.1007/s11095-010-0099-5 (2010). PubMed PMID: 20333451. Published, 07/2010.